Experimental Drug DT-109 Reverses Severe Fatty Liver Disease in Animal Studies by Targeting Gut Health

Scientists at Michigan Medicine have developed an experimental drug, DT-109, that successfully reversed metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease, in animal models. Published in *The Journal of Clinical Investigation*, the drug works by reducing harmful gut bacteria, protecting the intestinal lining, and preventing inflammatory substances from reaching the liver, offering a new therapeutic strategy for this difficult-to-manage condition.